STAT3 and colorectal carcinoma: IL-6 production by tumor cells may act as an autocrine and/or paracrine growth factor during carcinogenesis, and various studies have proposed promising targets for CRC therapy using anti-IL-6 and anti-IL-6R antibodies as well as soluble gp130Fc (sgp130Fc) and selective small-molecule JAK inhibitors that suppress the IL-6/STAT3 pathway (34).